Autocrine/paracrine erythropoietin regulates migration and invasion potential and the stemness of human breast cancer cells

Recent studies suggest that erythropoietin (EPO) has pleiotropic effects in several cell types in addition to hematopoietic cells; however, the role of EPO-mediated cell signaling in nonhematopoietic cells, including in cancer cells, remains controversial. Here, we report our findings of autocrine/paracrine production of EPO by breast cancer cells and its functional significance. We detected a significant level of autocrine/paracrine EPO in the conditioned medium from the culture of SKBR3 breast cancer cells, particularly when the cells were cultured in hypoxia. Through knockdown of EPO and EPO receptor expression and experimental elevation of EPO receptor expression in SKBR3 breast cancer cells, we demonstrated novel roles of autocrine/paracrine EPO-mediated cell signaling in regulating migration and invasion potential and stemness-like properties of breast cancer cells.

[1]  G. Landberg,et al.  Contrasting hypoxic effects on breast cancer stem cell hierarchy is dependent on ER-α status. , 2013, Cancer research.

[2]  Joana Paredes,et al.  Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types , 2012, Journal of Clinical Pathology.

[3]  R. Clarke,et al.  A Detailed Mammosphere Assay Protocol for the Quantification of Breast Stem Cell Activity , 2012, Journal of Mammary Gland Biology and Neoplasia.

[4]  B. Aggarwal,et al.  Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells , 2012, Breast Cancer Research.

[5]  Perry Maxwell,et al.  Autocrine/paracrine erythropoietin signalling promotes JAK/STAT‐dependent proliferation of human cervical cancer cells , 2011, International journal of cancer.

[6]  Yang Liu,et al.  Targeting HIF1α eliminates cancer stem cells in hematological malignancies. , 2011, Cell stem cell.

[7]  G. Mills,et al.  Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. , 2010, Cancer cell.

[8]  G. Semenza.  Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics , 2010, Oncogene.

[9]  G. Melillo,et al.  Development of HIF-1 inhibitors for cancer therapy , 2009, Journal of cellular and molecular medicine.

[10]  A. Sytkowski,et al.  An Erythropoietin Autocrine/Paracrine Axis Modulates the Growth and Survival of Human Prostate Cancer Cells , 2009, Molecular Cancer Research.

[11]  M. Tonelli,et al.  Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis , 2009, Canadian Medical Association Journal.

[12]  M. Zwahlen,et al.  Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials , 2009, The Lancet.

[13]  C. Noguchi,et al.  Survival and proliferative roles of erythropoietin beyond the erythroid lineage , 2008, Expert Reviews in Molecular Medicine.

[14]  A. Sytkowski,et al.  The erythropoietin receptor in normal and cancer tissues. , 2008, Critical reviews in oncology/hematology.

[15]  A. Cano,et al.  A hypoxic twist in metastasis , 2008, Nature Cell Biology.

[16]  W. McBride,et al.  Effects of recombinant erythropoietin on breast cancer-initiating cells. , 2007, Neoplasia.

[17]  M. Kampa,et al.  Erythropoietin and Its Receptor in Breast Cancer: Correlation with Steroid Receptors and Outcome , 2007, Cancer Epidemiology Biomarkers & Prevention.

[18]  S. Perrotta,et al.  Erythropoietin receptors on cancer cells: a still open question. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Grandis,et al.  Understanding the presence and function of erythropoietin receptors on cancer cells. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Dewhirst,et al.  Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity , 2006, Molecular Cancer Therapeutics.

[21]  F. Farrell,et al.  Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor–positive breast carcinoma models , 2006, Molecular Cancer Therapeutics.

[22]  M. Dewhirst,et al.  Erythropoietin Biology in Cancer , 2006, Clinical Cancer Research.

[23]  K. Eckardt,et al.  Regulation of erythropoietin production , 2005, Contributions to nephrology.

[24]  K. Garber.  New drugs target hypoxia response in tumors. , 2005, Journal of the National Cancer Institute.

[25]  C. V. van Groeningen,et al.  Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial. , 2005, European journal of cancer.

[26]  C. Lau,et al.  Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  D. Elder,et al.  Functional erythropoietin autocrine loop in melanoma. , 2005, The American journal of pathology.

[28]  C. Koch,et al.  Autocrine erythropoietin signaling inhibits hypoxia-induced apoptosis in human breast carcinoma cells. , 2004, Cancer letters.

[29]  C. Rübe,et al.  Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial , 2003, The Lancet.

[30]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[31]  A. Harris,et al.  Hypoxia‐induced pathways in breast cancer , 2002, Microscopy research and technique.

[32]  G. Semenza.  Involvement of hypoxia-inducible factor 1 in human cancer. , 2002, Internal medicine.

[33]  R. Bicknell,et al.  Hypoxia and oxidative stress in breast cancer: Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer , 2001, Breast Cancer Research.

[34]  Adrian L Harris,et al.  Hypoxia and oxidative stress in breast cancer: Hypoxia and tumourigenesis , 2001, Breast Cancer Research.

[35]  J. Nortier,et al.  Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  C. Westenfelder,et al.  Erythropoietin stimulates proliferation of human renal carcinoma cells. , 2000, Kidney international.

[37]  G. Semenza,et al.  Hypoxia, Clonal Selection, and the Role of HIF-1 in Tumor Progression , 2000, Critical reviews in biochemistry and molecular biology.

[38]  P. Carmeliet,et al.  Role of HIF-1 alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis (vol 394, pg 485, 1998) , 1998 .

[39]  G. Semenza,et al.  Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[40]  G. Semenza,et al.  Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. , 1994, The Journal of biological chemistry.

[41]  P. Ratcliffe,et al.  Inducible operation of the erythropoietin 3' enhancer in multiple cell lines: evidence for a widespread oxygen-sensing mechanism. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[42]  M. Goldberg,et al.  Regulation of erythropoietin production. , 1993, Experimental hematology.

[43]  E. Goldwasser,et al.  Purification of human erythropoietin. , 1977, The Journal of biological chemistry.

[44]  M. Gordon,et al.  Recombinant Human Erythropoietin and Overall Survival in Cancer Patients: Results of a Comprehensive Meta-analysis , 2006 .

[45]  M. Arcasoy,et al.  Functional Significance of Erythropoietin Receptor Expression in Breast Cancer , 2002, Laboratory Investigation.

[46]  P. Mayeux,et al.  The molecular biology of erythropoietin. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[47]  G. Semenza,et al.  Molecular basis of hypoxia‐induced erythropoietin expression , 1996, Current opinion in hematology.

[48]  J. Egrie,et al.  Erythropoietin: gene cloning, protein structure, and biological properties. , 1986, Cold Spring Harbor symposia on quantitative biology.

[49]  M. Sporn,et al.  Autocrine, paracrine and endocrine mechanisms of growth control. , 1985, Cancer surveys.

[50]  Sporn Mb,et al.  Autocrine, paracrine and endocrine mechanisms of growth control. , 1985 .